Trials
4 active
4 in total · 3 in the EU
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Muscular Atrophy, Spinal (3 trials), Spinal Muscular Atrophy
- Main trialPhase 3
- “In this study, researchers will learn more about the effects and safety of BIIB115, also known as salanersen. Specifically, researchers will learn more about how salanersen works in individuals with SMA who are between the ages of 15 and 60 years old. In most people living with SMA, changes to or a lack of a gene called survival motor neuron 1 (SMN1) - often referred to as gene mutations or variants - affect how this gene works. As a result, their bodies produce less SMN protein. Without enough of this protein, motor neurons and muscles cannot work properly. There is a similar gene called…”In the company’s words, NCT07444476 on ClinicalTrials.gov
- Other names
- BIIB115
Other drugs for Muscular Atrophy, Spinal
- BMS-986365Celgene · Phase 3
- NusinersenBiogen · Phase 3
- RinzimetostatORIC Pharmaceuticals · Phase 3
- ApitegromabScholar Rock · Phase 3
- Taldefgrobep alfaBiohaven · Phase 3
- Vesemnogene lantuparvovecLantu Biopharma · Phase 1/2
Coming up4
- 23 Jun 2028Phase 3 trial completes · ClinicalTrials.gov
- 28 Nov 2028Phase 3 trial completes · ClinicalTrials.gov
- 27 Jul 2029Phase 3 trial completes · ClinicalTrials.gov
- 14 Nov 2031Phase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials4
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | 23 Jun 2028 | A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety in Participants Aged 15 to 60 Years With Spinal Muscular Atrophy (SMA) Who Are Either New to SMA Treatment or Were Previously Treated With Risdiplam | |
| Phase 3Recruiting | 28 Nov 2028 | A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety When Given Before Symptoms Appear in Babies With Genetically Diagnosed Spinal Muscular Atrophy (SMA) | |
| Phase 3Recruiting | 27 Jul 2029 | A Study to Learn About the Safety and Effects of Salanersen (BIIB115) When Given to Babies With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Onasemnogene Abeparvovec | |
| Phase 1Active, not recruiting | 14 Nov 2031 | A Study to Learn About the Safety of BIIB115 Injections and How BIIB115 is Processed in the Bodies of Healthy Adult Male Volunteers and of Pediatric Participants With Spinal Muscular Atrophy Who Previously Took Onasemnogene Abeparvovec |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026